FDA Reaffirms Proteinuria Endpoint for FSGS: Positive Signal for Travere Therapeutics
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in Travere Therapeutics' upcoming Filspari decision.
/ 907 items
#Healthcare↓
FDA Approves First-Ever Treatment for Deadly Stem Cell Transplant Complication
Omeros' (OMER) Yartemlea becomes the first FDA-approved drug for TA-TMA, a life-threatening complication affecting stem cell transplant patients, with launch planned for January 2026.
Eli Lilly Eyes French Biotech Abivax for Ulcerative Colitis Drug Deal
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.
Edgewise EDG-7500 Shows Promising Heart Disease Trial Results
Edgewise Therapeutics (EWTX) shares positive safety data from EDG-7500 trial for hypertrophic cardiomyopathy, showing no heart function decline with comprehensive results expected in Q2 2026.
Gilead Acquires Repare's Cancer Drug for $30 Million
Gilead Sciences purchases RP-3467, a promising cancer treatment targeting BRCA mutations, from Repare Therapeutics in a deal worth up to $30 million.
Sanofi Acquires Dynavax for $2.2 Billion to Boost Vaccine Portfolio
French drugmaker Sanofi agrees to purchase U.S. vaccines company Dynavax Technologies for $2.2 billion, gaining access to hepatitis B vaccine and experimental shingles shot.